OBJECTIVES: Higher CSF antiretroviral concentrations may be associated with better control of HIV replication and neurocognitive performance, but only the unbound fraction of antiretrovirals is available to inhibit HIV. Therefore, the objective of this study was to determine total and unbound darunavir concentrations in CSF and compare findings with plasma concentrations as well as the wild-type HIV-1 90% inhibitory concentration (IC(90)). METHODS: Subjects with HIV infection were selected based on the use of darunavir-containing regimens with a twice-daily dosing schedule and availability of stored CSF and matched plasma. Total darunavir was measured by HPLC for plasma or liquid chromatography-tandem mass spectroscopy (LC/MS/MS) for CSF. Plasma unbound darunavir was measured by ultrafiltration and LC/MS/MS. CSF protein binding was determined by competitive binding exchange with radiolabelled darunavir. RESULTS: Twenty-nine matched CSF-plasma pairs were analysed and darunavir was detected in all CSF specimens (median total concentration 55.8 ng/mL), with a CSF unbound fraction of 93.5%. Median fractional penetrance was 1.4% of median total and 9.4% of median unbound plasma concentrations. Unbound darunavir concentrations in CSF exceeded the median IC(90) for wild-type HIV in all subjects by a median of 20.6-fold, despite the relatively low fractional penetrance. Total darunavir concentrations in CSF correlated with both total and unbound darunavir concentrations in plasma. CONCLUSIONS: Darunavir should contribute to the control of HIV replication in the CNS as a component of effective combination antiretroviral regimens.
OBJECTIVES: Higher CSF antiretroviral concentrations may be associated with better control of HIV replication and neurocognitive performance, but only the unbound fraction of antiretrovirals is available to inhibit HIV. Therefore, the objective of this study was to determine total and unbound darunavir concentrations in CSF and compare findings with plasma concentrations as well as the wild-type HIV-1 90% inhibitory concentration (IC(90)). METHODS: Subjects with HIV infection were selected based on the use of darunavir-containing regimens with a twice-daily dosing schedule and availability of stored CSF and matched plasma. Total darunavir was measured by HPLC for plasma or liquid chromatography-tandem mass spectroscopy (LC/MS/MS) for CSF. Plasma unbound darunavir was measured by ultrafiltration and LC/MS/MS. CSF protein binding was determined by competitive binding exchange with radiolabelled darunavir. RESULTS: Twenty-nine matched CSF-plasma pairs were analysed and darunavir was detected in all CSF specimens (median total concentration 55.8 ng/mL), with a CSF unbound fraction of 93.5%. Median fractional penetrance was 1.4% of median total and 9.4% of median unbound plasma concentrations. Unbound darunavir concentrations in CSF exceeded the median IC(90) for wild-type HIV in all subjects by a median of 20.6-fold, despite the relatively low fractional penetrance. Total darunavir concentrations in CSF correlated with both total and unbound darunavir concentrations in plasma. CONCLUSIONS:Darunavir should contribute to the control of HIV replication in the CNS as a component of effective combination antiretroviral regimens.
Authors: J J Sevigny; S M Albert; M P McDermott; J C McArthur; N Sacktor; K Conant; G Schifitto; O A Selnes; Y Stern; D R McClernon; D Palumbo; K Kieburtz; G Riggs; B Cohen; L G Epstein; K Marder Journal: Neurology Date: 2004-12-14 Impact factor: 9.910
Authors: R J Ellis; K Hsia; S A Spector; J A Nelson; R K Heaton; M R Wallace; I Abramson; J H Atkinson; I Grant; J A McCutchan Journal: Ann Neurol Date: 1997-11 Impact factor: 10.422
Authors: J C McArthur; D R McClernon; M F Cronin; T E Nance-Sproson; A J Saah; M St Clair; E R Lanier Journal: Ann Neurol Date: 1997-11 Impact factor: 10.422
Authors: R J Ellis; A C Gamst; E Capparelli; S A Spector; K Hsia; T Wolfson; I Abramson; I Grant; J A McCutchan Journal: Neurology Date: 2000-02-22 Impact factor: 9.910
Authors: Pavel Adam; Ondrej Sobek; Ludek Táborský; Thomas Hildebrand; Olga Tutterová; Petr Zácek Journal: Clin Chim Acta Date: 2003-08 Impact factor: 3.786
Authors: Scott L Letendre; J Allen McCutchan; Meredith E Childers; Steven P Woods; Deborah Lazzaretto; Robert K Heaton; Igor Grant; Ronald J Ellis Journal: Ann Neurol Date: 2004-09 Impact factor: 10.422
Authors: Ronald J Ellis; David J Moore; Meredith E Childers; Scott Letendre; J Allen McCutchan; Tanya Wolfson; Stephen A Spector; Karen Hsia; Robert K Heaton; Igor Grant Journal: Arch Neurol Date: 2002-06
Authors: David W Haas; Benjamin Johnson; Janet Nicotera; Vicki L Bailey; Victoria L Harris; Farideh B Bowles; Stephen Raffanti; Jennifer Schranz; Tyler S Finn; Alfred J Saah; Julie Stone Journal: Antimicrob Agents Chemother Date: 2003-07 Impact factor: 5.191
Authors: Babafemi Taiwo; Edward P Acosta; Patrick Ryscavage; Baiba Berzins; Darlene Lu; Jay Lalezari; Jose Castro; Oluwatoyin Adeyemi; Daniel R Kuritzkes; Joseph J Eron; Athe Tsibris; Susan Swindells Journal: J Acquir Immune Defic Syndr Date: 2013-10-01 Impact factor: 3.731
Authors: Anh Nguyen; Steven Rossi; David Croteau; Brookie M Best; David Clifford; Ann C Collier; Benjamin Gelman; Christina Marra; Justin McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Ronald J Ellis; Igor Grant; Edmund Capparelli; Scott Letendre Journal: J Antimicrob Chemother Date: 2013-01-20 Impact factor: 5.790